Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.
about
Oral paliperidone for schizophreniaAntipsychotic-induced hyperprolactinemiaThe effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder.Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies.The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary studyA 64-week, multicenter, open-label study of aripiprazole effectiveness in the management of patients with schizophrenia or schizoaffective disorder in a general psychiatric outpatient setting.Metabolic, digestive, and reproductive adverse events associated with antimanic treatment in children and adolescents: a retrospective cohort study.The diagnosis and treatment of bipolar disorder: decision-making in primary care.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trialsHyperprolactinemia during antipsychotics treatment increases the level of coagulation markers.Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trialsHigh prevalence of chronic pituitary and target-organ hormone abnormalities after blast-related mild traumatic brain injuryProlactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic reviewOsteoporosis and fracture risk in people with schizophreniaManagement of psychosis associated with a prolactinoma: case report and review of the literatureSecondary effects of antipsychotics: women at greater risk than men.Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidoneTeratogenicity and hyperprolactinemia.A review of the safety and tolerability of aripiprazole.Sex differences in the psychopharmacological treatment of depression.Hyperprolactinaemia during treatment with paliperidone.Schizophrenia: women bear a disproportionate toll of antipsychotic side effects.A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: clinical and research implications.Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review.Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review.Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials.Comparison of treatment patterns in schizophrenia between China and Japan (2001-2009).Sexual dysfunction and hyperprolactinemia in male psychotic inpatients: a cross-sectional study.Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia.The search for new biomarkers for cognition in schizophrenia.Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients.Common use of high doses of antipsychotic medications in older Asian patients with schizophrenia (2001-2009).Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China.Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.Drug-induced gynecomastia
P2860
Q24242948-6F988553-4424-4B13-A14E-255FEC52E10EQ28305237-5A0A31FD-B303-43DD-AC27-E3375AFC7167Q33619940-8F6DF709-9A7A-4568-A1BA-8A32B60F87B6Q34027230-B8174460-4EC2-469E-BCF7-BC36D565F0A5Q34027550-4A5E9C78-25A6-46CC-9D6D-7AA51ACA374BQ34110039-DA7DA0A0-F391-43A0-A371-83F6C790E7E0Q34174609-C7BE3758-7368-4CE5-BFE6-1C0D9CC0941CQ34318121-446D6A7A-9580-4639-B846-EF82A01C409DQ34331882-E547D408-B537-4A6D-84D0-5B68AD905FA6Q34623350-B1D26F0C-7E9A-492D-B16C-AB8DE5E1A2A0Q34925151-0319930D-6FA5-45EF-913F-C3098754E4B8Q35142660-8E45267A-3CA4-4C18-BDA7-7682DB6AC375Q35214820-95515306-D9CC-4F7B-9692-314C6F3EE2FEQ35740384-8B558B78-A685-4690-8B6B-131C52EAC770Q36186039-18950FC3-8FA5-435E-A14C-26AE4D5307F8Q36592205-A3290F8F-93BB-432F-A943-D2C3BDCB5389Q36888242-CF942871-6C4A-42E8-92D7-6BD6CC5C7B42Q37133664-CB368C1A-0248-43DF-80F6-6632EF7A4382Q37155297-7A9A3360-4084-4B3B-981C-CF72F3682CBEQ37334220-B977639D-DD4E-4AF0-B6F9-F2402ED56A82Q37510958-C224A573-9FF6-4D63-B22C-DB691C66F5C6Q37618539-CD3D65A2-1945-4004-9A92-509D59B1513EQ37739435-6558B905-91E5-4C84-951A-FDFFC8A93242Q37887304-DF629A71-943C-457E-BC28-475F977DFBEBQ37998841-D74FCEFD-47B4-43F7-ACEB-DFE4E88C2CE0Q37999566-2A37DD56-B7B7-4807-80A3-7B56CD53C098Q38201749-8225B6F3-6592-4306-8E80-18DED6C40C23Q38778145-CD0A4E1B-5E48-4377-BD64-2CF5B9455457Q38858121-620199CF-1E33-442E-B6D4-816FFA1FA65BQ38950803-FD225E98-DB87-4471-849D-ECBA0B92ACAFQ39726164-4C570A22-9E02-4DEB-8620-040B4A6D1B77Q40626667-88BB0E54-0C8E-4009-8A75-82BA1DAD8FC3Q43376611-B0BF481E-62C3-420F-82F1-E539B3ED995BQ43489252-4D903709-0E96-4CE0-876A-150F91EC3DD3Q45835487-99CE92D6-043D-4E56-A431-6F0CBC5223FCQ48397820-E700E36D-E5D3-4424-9290-0F9659B1A82BQ48918400-3E6778D9-338C-40CE-8DA0-ABE035C710CBQ57258716-9D2399E4-46D2-46F3-A58E-102C4DE726FE
P2860
Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical implications of antip ...... ents and current perspectives.
@en
Clinical implications of antip ...... ents and current perspectives.
@nl
type
label
Clinical implications of antip ...... ents and current perspectives.
@en
Clinical implications of antip ...... ents and current perspectives.
@nl
prefLabel
Clinical implications of antip ...... ents and current perspectives.
@en
Clinical implications of antip ...... ents and current perspectives.
@nl
P2093
P1476
Clinical implications of antip ...... ents and current perspectives.
@en
P2093
Matthew Byerly
Quynh-Van Tran
Ross A Baker
Trisha Suppes
P304
P356
10.1097/JCP.0B013E31815AC4E5
P407
P577
2007-12-01T00:00:00Z